<html><head></head><body><h1>Rynatuss Tablets</h1><p class="drug-subtitle"><b>Generic Name:</b> carbetapentane tannate, chlorpheniramine tannate, ephedrine tannate, and phenylephrine tannate<br/>
<b>Dosage Form:</b> tablet<br/></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Dosage</li>
<li><b class="nav-item here">Professional</b></li>
<li>Interactions</li>
<li>Images</li>
<li class="nav-more">
More&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewBox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/body&gt;&lt;/html&gt;
</li>
</ul><p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.</p><ul>
<li>Description</li>
<li>Clinical Pharmacology</li>
<li>Indications and Usage</li>
<li>Contraindications</li>
<li>Warnings</li>
<li>Precautions</li>
<li>Patient Counseling Information</li>
<li class="ddc-toggle-hidden">Drug Interactions</li>
<li class="ddc-toggle-hidden">Adverse Reactions/Side Effects</li>
<li class="ddc-toggle-hidden">Overdosage</li>
<li class="ddc-toggle-hidden">Dosage and Administration</li>
<li class="ddc-toggle-hidden">How Supplied/Storage and Handling</li>
</ul><h2>Description</h2><p class="First">RYNATUSS<span class="Sup">®</span> Tablets are an antitussive/antihistamine/nasal decongestant/bronchodilator combination.</p><p>Each tablet contains:<br/>
Carbetapentane Tannate               60 mg<br/>
Chlorpheniramine Tannate               5 mg<br/>
Ephedrine Tannate                          10 mg<br/>
Phenylephrine Tannate                   10 mg</p><p>Other ingredients: corn starch, dibasic calcium phosphate, FD&amp;C Blue No. 1, FD&amp;C Red No. 40, magnesium stearate, methylcellulose, polygalacturonic acid, povidone, talc.</p><h2>Clinical Pharmacology</h2><p class="First">RYNATUSS<span class="Sup">®</span> Tablets combine the antitussive action of carbetapentane, the sympathomimetic decongestant effect of phenylephrine, the antihistaminic action of chlorpheniramine, and the bronchodilator action of ephedrine.</p><h2>Indications and Usage</h2><p class="First">RYNATUSS<span class="Sup">®</span> Tablets are indicated for the symptomatic relief of cough associated with respiratory tract conditions such as the common cold, bronchial asthma, acute and chronic bronchitis. Appropriate therapy should be provided for the primary disease.</p><h2>Contraindications</h2><p class="First">RYNATUSS<span class="Sup">®</span> Tablets are contraindicated for newborns, nursing mothers, and patients who are sensitive to any of the ingredients or related compounds.</p><h2>Warnings</h2><p class="First">Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes, narrow angle glaucoma, or prostatic hypertrophy. Do not use in patients taking monoamine oxidase (MAO) inhibitors, or for 14 days after stopping treatment with an MAOI.</p><p>This product contains an antihistamine which may cause drowsiness and may have additive central nervous system (CNS) effects with alcohol or other CNS depressants (e.g., hypnotics, sedatives, tranquilizers).</p><h2>Precautions</h2><p class="First"><span class="Italics">General:</span> Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients. Antihistamines may cause excitation, particularly in children, but their combination with sympathomimetics may cause either mild stimulation or mild sedation.</p><p class="First"><span class="Italics">Information for patients:</span> Caution patients against drinking alcoholic beverages or engaging in potentially hazardous activities requiring alertness, such as driving a car or operating machinery, while using this product. Patients should be warned not to use this product if they are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If patients are uncertain whether a prescription drug contains an MAOI, they should be instructed to consult a health professional before taking such a product.</p><p class="First"><span class="Italics">Drug interactions:</span> MAO inhibitors may prolong and intensify the anticholinergic effects of antihistamines and the overall effects of sympathomimetic agents.</p><p class="First"><span class="Italics">Carcinogenesis, mutagenesis, impairment of fertility:</span> No long term animal studies have been performed with RYNATUSS<span class="Sup">®</span> Tablets.</p><p class="First"><span class="Italics">Pregnancy:</span> Teratogenic effects: Pregnancy Category C. Animal reproduction studies have not been conducted with RYNATUSS<span class="Sup">®</span> Tablets. It is also not known whether RYNATUSS<span class="Sup">®</span> Tablets can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. RYNATUSS<span class="Sup">®</span> Tablets should be given to a pregnant woman only if clearly needed.</p><p class="First"><span class="Italics">Nursing mothers:</span> RYNATUSS<span class="Sup">®</span> Tablets should not be administered to a nursing woman.</p><h2>Adverse Reactions</h2><p class="First"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or</span> <span class="Bold Italics Underline">www.fda.gov/medwatch</span><span class="Bold">.</span></p><p>Adverse effects associated with RYNATUSS<span class="Sup">®</span> Tablets at recommended doses have been minimal. The most common have been drowsiness, sedation, dryness of mucous membranes, and gastrointestinal effects. Serious side effects with oral antihistamines or sympathomimetics have been rare.</p><h2>Overdosage</h2><p class="First"><span class="Italics">Signs and symptoms:</span> May vary from CNS depression to stimulation (restlessness to convulsions). Antihistamine overdosage in young children may lead to convulsions and death. Atropine-like signs and symptoms may be prominent.</p><p><span class="Italics">Treatment:</span> Induce vomiting if it has not occurred spontaneously. Precautions must be taken against aspiration especially in infants, children, and comatose patients. If gastric lavage is indicated, isotonic or half-isotonic saline solution is preferred. Stimulants should not be used. If hypotension is a problem, vasopressor agents may be considered.</p><h2>Dosage and Administration</h2><p class="First">Administer the recommended dose every 12 hours.<br/>
<span class="Italics">RYNATUSS<span class="Sup">®</span> Tablets:</span> Adults — 1 to 2 tablets.</p><h2>How Supplied</h2><p class="First">RYNATUSS<span class="Sup">®</span> Tablets are mauve, capsule-shaped, scored on one side and imprinted RYNATUSS 717 on the other side, containing in each tablet: carbetapentane tannate 60 mg, chlorpheniramine tannate 5 mg, ephedrine tannate 10 mg, phenylephrine tannate 10 mg, available in bottles of 100 (NDC 0037-0717-92).</p><p class="First"><span class="Italics">Storage:</span> Store at controlled room temperature 20°-25°C (68°-77°F).</p><p>Dispense in a tight container.</p><p>Protect from moisture.</p><p>Produced under license from<br/>
JFC Technologies<br/>
Bound Brook, NJ, U.S.A.</p><p>U.S. Patents 5,599,846; 5,663,415</p><p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or</span> <span class="Bold Italics Underline">www.fda.gov/medwatch</span><span class="Bold">.</span></p><p><span class="Bold">MEDA Pharmaceuticals<span class="Sup">®</span><br/>
Meda Pharmaceuticals Inc.</span><br/>
Somerset, New Jersey 08873-4120</p><p>Printed in U.S.A.               Rev. 1/09</p><p class="First"><span class="Bold">Package Label - Principal Display Panel – 100 Tablet Bottle</span></p><p>NDC 0037-0717-92<br/>
<span class="Bold">100 Tablets<br/>
RYNATUSS<span class="Sup">®</span></span><br/>
(carbetapentane tannate,<br/>
chlorpheniramine tannate,<br/>
ephedrine tannate,<br/>
phenylephrine tannate)</p><p>Each tablet contains:<br/>
Carbetapentane Tannate          60 mg<br/>
Chlorpheniramine Tannate          5 mg<br/>
Ephedrine Tannate                     10 mg<br/>
Phenylephrine Tannate              10 mg<br/>
<span class="Bold">Rx Only<br/>
MEDA Pharmaceuticals™</span><br/>
LB-071701-09 Rev. 2/08<br/>
<span class="Bold">Usual Dosage:</span> See package insert.<br/>
Store at controlled room temperature<br/>
20°-25°C (68°-77°F).<br/>
Protect from moisture.<br/>
Dispense in a tight container.<br/>
<span class="Bold">Tablet shade may vary among<br/>
lots; identity and purity of drug<br/>
are unaffected.</span><br/>
Produced under license from<br/>
JFC Technologies<br/>
Bound Brook, NJ U.S.A.<br/>
U.S. Patents 5,599,846; 5,663,415<br/>
<span class="Bold">MEDA Pharmaceuticals™<br/>
Meda Pharmaceuticals Inc.<br/>
Somerset, New Jersey 08873-4120</span><br/></p><p></p><h2>More about Rynatuss (carbetapentane / chlorpheniramine / ephedrine / phenylephrine)</h2><ul class="more-resources-list more-resources-list-general">
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Drug class: upper respiratory combinations</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>